FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

JAN 1 1 2006

ATTY. DOCKET NO. ON/4-32602A APPLICATION NO. 10/521,928 APPLICANT BHATNAGAR ET AL. FILING DATE JANUARY 21, 2005

Group

U.S. PATENT DOCUMENTS

No.	EVELY						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/S.1./	AA	4,617,307	10/14/86	Browne	514	300	06/20/84
/S.J./	AB	4,687,767	08/18/87	Bosies et al.	514	89	07/26/85
/S.J./	AC	4,749,713	06/07/88	Bowman et al.	514	341	03/07/86
/S.J./	AD	4,777,163	10/11/88	Bosies et al.	514	80	07/24/87
/S.J./	AE	4,939,130	07/03/90	Jaeggi et al.	514	94	02/27/89
7 0 10 11	AF						
	AG						
	АН						
	ΑI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
AM							
AN							
AO							
AP							
AQ							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.)

/S.J./	AR	Adjuvant Treatment of Postmenopaus Randomised Trial", Lancet, Vol. 359, N	
	AS	Intravenous Pamidronate: Results roo Multimational Cooperative Group, J Cli	Bone Metastases in Breast Cancer Patients Treated with a side time time of a supply of the Aredia of the Controlled Trial.", The Aredia of Controlled Trial. The Aredia of Controlled Trial.
/S.J./	АТ	Bisphosphonate in Breast Cancer Pati of a Pilot Experience". Eur J Intern Me	alliative Hormone Therapy, Low-dose Chemotherapy, and ents with Bone Marrow Involvement and Pancytopenia: Report d, Vol. 11, No. 6, pp. 329-333 (2000).
EXAMIN	NER	/Sahar Javanmard/	DATE CONSIDERED 09/25/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION
(Use several sheets (Linecessary)

JAN 1 1 2006

ATTY. DOCKET NO. ON/4-32602A APPLICATION NO. 10/521,928 APPLICANT BHATNAGAR ET AL. FILING DATE **JANUARY 21, 2005**

Group

EXAMINER INITIAL

DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/S.J./	DA	Gasser et al., "Intravenous Administration of Zoledronic Acid Prevents the Bone Loss and Reduction of Mechanical Properties Induced by Aromatase Inhibition or Surgical Ovariectomy in
/S.J./	DB	Rats", St. Gallen Breast Cancer Meeting (March 2003) and Osaka, IBMS-JSBMR (June 2003). Gnant et al., "Changes in Bone Mineral Density Caused by Anastrozole or Tamoxifen in Combination with Gosereline (± Zoledronate) as Adjuvant Treatment for Hormone Receptorpositive Premenopausal Breast Cancer: Results of a Randomized Multicenter Trial", Breast Cancer Research and Treatment, Contents Vol. 76, Suppl. 1, Abstract No. 12, p. S31 (2002).
	DC	*Harvey et al., "Issues Concerning the Role of Chemotherapy and Hormonal Therapy of Bone Metastases from Breast Carcinoma", Cancer, Vol. 66, Suppl. 6, pp. 1545-1651 (1997).
S.J./	DD	Hausmaninger, "Zoledronic Acid Prevents Bone Mineral Density Loss in Premenopausal Women Receiving Adjuvant Treatment for Hormone Receptor-positive Breast Cancer: Preliminary Results of a Randomized, Multicenter Trial of Zoledronic Acid in Patients Receiving Anastrozole or Tamoxifen in Combination with Goserelin", <i>The Breast, Primary Therapy of Early Breast Cancer</i> , 8 th Int. Conference, Vol. 12, Suppl. 1, Abstract P101, p. S43, (2003).
	DE	"Liersch et al., "Fernmetastasen Chirurgie beim Mammakarzinon", Viszeralchirurgie, Vol. 37, pp. 157-165 (2002).
	DF	Martindale, The Extra Pharmacopoeia, 31 st Edition, Reynolde, Ed., Royal Pharmaceutical Society, pp. 575, 781 and 782 (1996).
	DG	*Powles et al., "Breast Cancer Chemoprevention", The Breast, Vol. 10, pp. 56-61 (2001).
/S.J./	DH	Ravdin, "Aromatase Inhibitors for the Endocrine Adjuvant Treatment of Breast Cancer", Lancet, Vol. 359, No. 9324, pp. 2126-2127 (2002).
	DI	
· · · · · · · · · · · · · · · · · · ·	DJ	
	DK	·
	DL	
	DM	
	DN	
EXAMINE	R	/Sahar Javanmard/ DATE CONSIDERED 09/25/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.